Kinaset launches with $40M and a JAK inhibitor from Vectura's old pipeline

Nicole DeFeudis

Editor

Kinaset Therapeutics is joining the search for a better severe asthma treatment, picking up where Vectura left off when it decided to clear house last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kinaset launches with $40M and a JAK inhibitor from Vectura's old pipeline

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ki­naset launch­es with $40M and a JAK in­hibitor from Vec­tura's old pipeline

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Kinaset launches with $40M and a JAK inhibitor from Vectura's old pipeline